Peter Ho

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 614 citations

Medicine, Oncology, Pharmacology +12

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016

Wenle Xia, Lei-Hua Liu, Peter Ho et al. · Oncogene · 2004 · 253 citations

Life Sciences, Molecular Biology, Pharmacology +10

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <i>In Vitro</i> and <i>In Vivo</i> Preclinical Models

Elayne Chan-Penebre, Kelli Armstrong, Allison E. Drew et al. · Molecular Cancer Therapeutics · 2017 · 168 citations

Medicine, Molecular Biology, Oncology +17

Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer

Anna Maria Storniolo, Mark D. Pegram, Beth Overmoyer et al. · Journal of Clinical Oncology · 2008 · 119 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma

Steven O’Day, Anna C. Pavlick, Carmen Loquai et al. · British Journal of Cancer · 2011 · 118 citations · Full text

Medicine, Oncology, Pharmacology +16